Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
Wei‐Fan Hsu(China Medical University), Cheng‐Yuan Peng(China Medical University), Po‐Heng Chuang(China Medical University), Sheng‐Hung Chen(China Medical University), Hung‐Yao Chen(China Medical University), Hung‐Wei Wang(China Medical University), Hsueh‐Chou Lai(China Medical University), Guan‐Tarn Huang(National Taiwan University Hospital), Chia‐Hsin Lin(China Medical University), Wen‐Pang Su(China Medical University)
Cited by 73
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
|The Lancet|2014|343
Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.
|Molecular and Cellular Biology|1994|284